Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High

Today's Daily Dose brings you news about Amgen's chronic migraine study; Ampio's non compliance with certain listing standards of NYSE; Kura's phase II trial of Tipifarnib; Adamas' phase Ib epilepsy trial and AbbVie's phase IIb dose-ranging study of Upadacitinib in atopic dermatitis.

from RTT - Biotech http://ift.tt/2gNym80
via IFTTT